[Clinical progress of neutralizing antibodies against SARS-CoV-2].
Sheng Wu Gong Cheng Xue Bao
; 38(6): 2061-2068, 2022 Jun 25.
Artículo
en Chino
| MEDLINE | ID: covidwho-1912221
ABSTRACT
Since the palivizumab for respiratory syncytial virus was approved in 1998, therapeutic antibodies against infectious diseases have been widely used in clinical treatment. Since the outbreak of COVID-19, plenty of neutralizing antibodies were developed and transferred into clinical trials, holding enormous promise for the treatment of COVID-19 under the context of emergency use authorization. This review summarizes the clinical progress of these drugs, in order to provide a reference for the research and development of neutralizing antibody drugs for the future.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Anticuerpos Neutralizantes
/
COVID-19
Tipo de estudio:
Estudio pronóstico
Límite:
Humanos
Idioma:
Chino
Revista:
Sheng Wu Gong Cheng Xue Bao
Asunto de la revista:
Biotecnologia
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
J.cjb.220118
Similares
MEDLINE
...
LILACS
LIS